161 related articles for article (PubMed ID: 7833096)
1. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
Buccheri G; Ferrigno D
Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
[TBL] [Abstract][Full Text] [Related]
4. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
6. Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study.
Salvati F; Antilli A; Cruciani AR; Lombardi A; Mugnaini L; Nunziati F; Perrone N; Portalone L; Signora M
Tumori; 1995; 81(1):48-51. PubMed ID: 7754542
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients.
Buccheri G; Ferrigno D; Vola F; Curcio A
Oncology; 1989; 46(4):212-6. PubMed ID: 2544837
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
Chahinian AP; Propert KJ; Ware JH; Zimmer B; Perry MC; Hirsh V; Skarin A; Kopel S; Holland JF; Comis RL
J Clin Oncol; 1989 Aug; 7(8):993-1002. PubMed ID: 2547030
[TBL] [Abstract][Full Text] [Related]
11. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
[TBL] [Abstract][Full Text] [Related]
12. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.
Morton RF; Jett JR; McGinnis WL; Earle JD; Therneau TM; Krook JE; Elliott TE; Mailliard JA; Nelimark RA; Maksymiuk AW
Ann Intern Med; 1991 Nov; 115(9):681-6. PubMed ID: 1656827
[TBL] [Abstract][Full Text] [Related]
13. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
14. Changes in pulmonary surfactant composition following MACC chemotherapy for lung carcinoma.
Rossi GA; Balbi B; Benatti U; Morelli A; Sacco O; Vassallo F; Ravazzoni C
Eur J Respir Dis; 1987 Nov; 71(5):400-9. PubMed ID: 2832202
[TBL] [Abstract][Full Text] [Related]
15. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study.
Buccheri GF; Ferrigno D; Curcio A; Vola F; Rosso A
Cancer; 1989 Feb; 63(3):428-32. PubMed ID: 2536288
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
[TBL] [Abstract][Full Text] [Related]
17. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
Robinson E; Haim N; Segal R; Veseley Z; Mekori T
Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
